• Virtual Tour
  • Media
  • NEWS
  • Contact Us
  • Patients

    NEUROLOGY

    CinnoVex
    ReciGen
    CinnoMer
    CinnoTec

    ONCOLOGY & HAEMATOLOGY

    PegaGen
    CinnaPoietin
    KidiPeg

    GYNECOLOGY & HORMONE

    Cinnal-f
    CinnaFact
    CinnaTropin
    Melitide

    RHEUMATOLOGY

    CinnoPar
    CinnoRA
  • Healthcare Professionals

    NEUROLOGY

    CinnoVex
    ReciGen
    CinnoMer
    CinnoTec

    ONCOLOGY & HAEMATOLOGY

    PegaGen
    CinnaPoietin
    KidiPeg

    GYNECOLOGY & HORMONE

    Cinnal-f
    CinnaTropin
    CinnaFact
    Melitide

    RHEUMATOLOGY

    CinnoPar
    CinnoRA
  • Capabilities

    Our Technology

    Business Development

    Our Manufacturing Sites

    Research and Development
  • About Us
    • Presidential Note
    • About CinnaGen
    • Mission Statement
    • Policy
    • Management Team
  • Search
    • Virtual Tour
    • Media
    • NEWS
    • Contact Us
                                             

Happy New Year


 

Jan2020 / PR /
Previuos News CinnaGen ilac has been established in 2019
Next News Researchers announced safety and effectiveness of ReciGen (interferon beta-1a 44 mcg manufactured by CinnaGen Co.) on COVID-19 patients
tags:
  • New year
More in this category:
  • Home
  • Happy New Year
Back top Top
 
 
SUBMIT
  • Our Family
  • CinnaGen
  • AryoGen
  • Aroko Bioengineering
  • Orchid Pharmed
  • Cinna Pakhsh Gen
  • CinnaGen İlaç
  • Useful Links
  • Iran FDO
  • Iran MOH
  • Contact Us
  • Contact Us
  • About CinnaGen
  • History
  • Mission
  • Vision
  • Values
  • Contact
  • Tel: +98 21 42815
    Fax: +98 21 88561575
    Address: No.2 , 7thSt., Simaye Iran St., Shahrak Gharb, Tehran, IRAN
    E-mail: cinnagen@cinnagen.com
Copyright Allright reserved by CinnaGen Co.
Design by Leemeetless Design Studio | Developed by Maze Group